Why Biogen Stock Topped the Market Today

Biogen stock gained nearly 2% after beating analyst estimates on both revenue ($2.7B, up 3% YoY) and adjusted EPS ($3.60 vs. $3.17 expected). The company's growth portfolio drove top-line improvement with 24% YoY revenue growth. Despite cutting full-year adjusted net income guidance to $12-$13 per share from $14.25-$15.25, investors remained positive as the company raised revenue guidance to mid-single-digit growth for 2025, signaling successful business pivot.